Why this biotech offers ‘far greater potential for value creation’
An Aussie biotech company that develops personalised therapies to treat cancer says it has reached “a promising point in its...
News
Biotechnology
News
Industry tailwinds spur bioplastics manufacturer into top line growth
Investing in biotech has become an increasingly attractive proposition for venture capitalists, but the sector can be hard to navigate...
News
Why now is an excellent time to invest: Leading biotech investor
Investing in biotech has become an increasingly attractive proposition for venture capitalists, but the sector can be hard to navigate...
News
FDA win: Cancer drug granted market exclusivity for blood cancer
The US Food and Drug Administration has granted ‘orphan drug designation’ to PTX-100 for the treatment of peripheral T-cell lymphomas,...
News
US patent granted for Aussie biotech’s unique binding systems
A key US patent for Prescient Therapeutics’ OmniCAR platform has been granted, the Australian biotech company has announced, ensuring protection...
News
Prescient unveils new platform after 18 months in stealth mode
Australian biotech company Prescient Therapeutics has publicly revealed its high-performing cell therapy enhancement platform named CellPryme-M, developed in collaboration with...
News
Prescient Therapeutics expands PTX-200 testing after fourth complete remission
Australian biotechnology company Prescient Therapeutics will expand testing of its PTX-200 drug after another patient suffering a deadly blood cancer,...
News
Prescient in strong financial position after productive quarter
Australian biotech company Prescient Therapeutics has ended the March quarter with a sizeable cash balance despite continued investment into research...
News
‘Exciting clinical and commercial opportunity’: Prescient
Australian biotechnology company Prescient Therapeutics is enrolling up to 12 new patients for the next round of trials on its...
News
Milestones struck as Prescient due to emerge from ‘stealth mode’ on new tech
Cancer-fighting biotech company Prescient Therapeutics has continued to hit its clinical and development milestones in the first half of the...